This is a working overview of Nicotinamide mononucleotide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-05 and is reviewed periodically as new material appears.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
| Property | Value | Notes |
|---|---|---|
| Systematic class | Pyridine nucleotide | Contains nicotinamide, ribose, and phosphate |
| Common form | beta-NMN | Anomeric configuration relevant to enzyme recognition |
| Molecular formula | C11H15N2O8P | As the free acid |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | Commonly associated with beta-D-NMN |
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
=== Commanding officers === 1950 Lt Col Mike Calvert, Royal Engineers 1951 Lt Col John Sloane, Argyll and Sutherland Highlanders 1953 Lt Col Oliver Brooke, Welch Regiment 1954 Lt Col Michael Osborn, West Yorkshire Regiment 1955 Lt Col George Lea, Lancashire Fusiliers and Parachute Regiment 1957 Lt Col Tony Deane-Drummond, Royal Signals 1960 Lt Col Ronald Dare Wilson, Royal Northumberland Fusiliers 1962 Lt Col John Woodhouse, Dorset Regiment and East Surreys 1965 Lt Col Michael Wingate-Gray, Black Watch 1967 Lt Col John Slim, Argyll and Sutherland Highlanders 1969 Lt Col John Watts, Royal Irish Rangers 1972 Lt Col Peter de la Billière, Light Infantry 1974 Lt Col Anthony Jeapes, Devonshire and Dorset Regiment 1977 Lt Col Mike Wilkes, Royal Artillery 1982 Lt Col Mike Rose, Coldstream Guards 1984 Lt Col Andrew Massey, Royal Corps of Transport 1986 Lt Col Cedric Delves, Devonshire and Dorset Regiment 1989 Lt Col John Holmes, Scots Guards n/k Lt Col Jonathan "Jacko" Page, Parachute Regiment 2001 Lt Col Ed Butler, Royal Green Jackets 2002 Lt Col Mark Carleton-Smith, Irish Guards 2007 Lt Col Richard Williams, Parachute Regiment 2012 Lt Col Nick Perry, King's Royal Hussars
The ascorbate-glutathione cycle, sometimes Foyer-Halliwell-Asada pathway, is a metabolic pathway that detoxifies hydrogen peroxide (H2O2), a reactive oxygen species that is produced as a waste product in metabolism. The cycle involves the antioxidant metabolites: ascorbate, glutathione and NADPH and the enzymes linking these metabolites. In the first step of this pathway, H2O2 is reduced to water by ascorbate peroxidase (APX) using ascorbate (ASC) as the electron donor. The oxidized ascorbate (monodehydroascorbate, MDA) is regenerated by monodehydroascorbate reductase (MDAR). However, monodehydroascorbate is a radical and if not rapidly reduced it disproportionates into ascorbate and dehydroascorbate (DHA). Dehydroascorbate is reduced to ascorbate by dehydroascorbate reductase (DHAR) at the expense of GSH, yielding oxidized glutathione (GSSG). Finally GSSG is reduced by glutathione reductase (GR) using NADPH as the electron donor. Thus ascorbate and glutathione are not consumed; the net electron flow is from NADPH to H2O2. The reduction of dehydroascorbate may be non-enzymatic or catalysed by proteins with dehydroascorbate reductase activity, such as glutathione S-transferase omega 1 or glutaredoxins. In plants, the glutathione-ascorbate cycle operates in the cytosol, mitochondria, plastids and peroxisomes. Since glutathione, ascorbate and NADPH are present in high concentrations in plant cells it is assumed that the glutathione-ascorbate cycle plays a key role for H2O2 detoxification.
==== MeSH E05.196.941 – ultracentrifugation ==== MeSH E05.196.941.336 – centrifugation, density gradient MeSH E05.196.941.336.253 – centrifugation, isopycnic MeSH E05.196.941.336.419 – centrifugation, zonal
Sources: en.wikipedia.org
==== Remdesivir/baricitinib ==== In May 2020, the National Institute of Allergy and Infectious Diseases (NIAID) started the Adaptive COVID‑19 Treatment Trial 2 (ACTT-2) to evaluate the safety and efficacy of a treatment regimen consisting of remdesivir plus baricitinib for treating hospitalized adults who have a laboratory-confirmed SARS-CoV-2 infection with evidence of lung involvement, including a need for supplemental oxygen, abnormal chest X-rays, or illness requiring mechanical ventilation. In November 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory-confirmed COVID‑19 in hospitalized people two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The data supporting the EUA for baricitinib combined with remdesivir are based on a randomized, double-blind, placebo-controlled clinical trial (ACTT-2), which was conducted by the National Institute of Allergy and Infectious Diseases (NIAID). The EUA was issued to Eli Lilly and Company.
=== Genetic diseases === Glycolytic mutations are generally rare due to importance of the metabolic pathway; the majority of occurring mutations result in an inability of the cell to respire, and therefore cause the death of the cell at an early stage. However, some mutations (glycogen storage diseases and other inborn errors of carbohydrate metabolism) are seen with one notable example being pyruvate kinase deficiency, leading to chronic hemolytic anemia. In combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3 deficiency, glycolysis is reduced by −50%, which is caused by reduced lipoylation of mitochondrial enzymes such as the pyruvate dehydrogenase complex and α-ketoglutarate dehydrogenase complex.
== Selectivity coefficient == The concept of selectivity is used to quantify the extent to which one chemical substance, A, binds each of two other chemical substances, B and C. The simplest case is where the complexes formed have 1:1 stoichiometry. Then, the two interactions may be characterized by equilibrium constants KAB and KAC.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.
NMN is a direct precursor in the salvage pathway that produces NAD+. Enzymes called NMN adenylyltransferases convert NMN into NAD+, a coenzyme involved in redox reactions and signaling.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Both can influence NAD+ pathways, but their structures, transport, and metabolism differ.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.